Driving new boundaries in drug development

Identifying and investigating new treatments to improve patient outcomes

Our pipeline

We are building a rich pipeline of assets in four main therapeutic spaces: immuno-oncology, inflammation, haematology and infectious diseases. Our most advanced assets entered development in 2015 with first proof of concepts scheduled for readout by 2019.

Download Pipeline PDF

Our Kymouse™ platform can deliver the finest novel therapeutic antibodies

Learn more